臨床眼科78巻12号

2024年11月発行

特集 ザ・脈絡膜。

脈絡膜と中心性漿液性脈絡網膜症

著者： 船津諒¹

所属機関： ¹鹿児島大学医学部眼科学教室

ページ範囲：P.1380 - P.1385

文献概要

●脈絡膜循環のうっ滞は中心性漿液性脈絡網膜症の原因の1つと考えられている。

●中心性漿液性脈絡網膜症における脈絡膜の形態異常は渦静脈近傍まで及ぶ。

●脈絡膜の肥厚・管腔拡大・血管透過性亢進は，中心性漿液性脈絡網膜症の診療に重要な所見である。

参考文献

1）Daruich A, Matet A, Marchionno L, et al：Acute central serous chorioretinopathy：factors influencing episode duration. Retina 37：1905-1915, 2017

2）Mrejen S, Balaratnasingam C, Kaden TR, et al：Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy. Ophthalmology 126：576-588, 2019

3）Miki A, Kusuhara S, Otsuji T, et al：Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy. PLoS One 16：e0248760, 2021

4）Spaide RF, Hall L, Haas A, et al：Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 16：203-213, 1996

5）Sonoda S, Sakamoto T, Kuroiwa N, et al：Structural changes of inner and outer choroid in central serous chorioretinopathy determined by optical coherence tomography. PLoS One 11：e0157190, 2016

6）Hiroe T, Kishi S：Dilatation of asymmetric vortex vein in central serous chorioretinopathy. Ophthalmol Retina 2：152-161, 2018

7）Kishi S, Matsumoto H, Sonoda S, et al：Geographic filling delay of the choriocapillaris in the region of dilated asymmetric vortex veins in central serous chorioretinopathy. PLoS One 13：e0206646, 2018

8）Imanaga N, Terao N, Nakamine S, et al：Scleral thickness in central serous chorioretinopathy. Ophthalmol Retina 5：285-291, 2021

9）Ishikura M, Muraoka Y, Nishigori N, et al：Widefield choroidal thickness of eyes with central serous chorioretinopathy examined by swept-source OCT. Ophthalmol Retina 6：949-956, 2022

10）Funatsu R, Sonoda S, Terasaki H, et al：Choroidal morphologic features in central serous chorioretinopathy using ultra-widefield optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 261：971-979, 2023

11）Spaide RF, Gemmy Cheung CM, Matsumoto H, et al：Venous overload choroidopathy：a hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retin Eye Res 86：100973, 2022

12）Warrow DJ, Hoang QV, Freund KB：Pachychoroid pigment epitheliopathy. Retina 33：1659-1672, 2013

13）Pang CE, Freund KB：Pachychoroid neovasculopathy. Retina 35：1-9, 2015

14）Yagi M, Miyake M, Mori Y, et al：Natural course of pachychoroid pigment epitheliopathy. Ophthalmol Sci 2：100201, 2022

15）Inoue R, Sawa M, Tsujikawa M, et al：Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. Am J Ophthalmol 149：441-446. e1-2, 2010

16）van Dijk EHC, Fauser S, Breukink MB, et al：Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy：the PLACE trial. Ophthalmology 125：1547-1555, 2018

17）Pauleikhoff LJB, Diederen RMH, Chang-Wolf JM, et al：Choroidal hyperpermeability patterns correlate with disease severity in central serous chorioretinopathy：CERTAIN study report 2. Acta Ophthalmol 102：e946-e955, 2024